Skip to main content
Equibles
CGEM logo

CGEM · Cullinan Therapeutics, Inc. · Metrics

Track CGEM — free

Use CGEM with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CGEM.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$14.84 +0.30 (+2.06%) At close · Oct 27
Russell 2000 member Rebalance outlook locked
Market Cap
$955.02M
Shares
64.35M
Volume · Oct 27 488.23K Avg daily vol (3M) 900.01K

CGEM metrics

73 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$14.84
Market cap
$955.02M

Price action

20 metrics
Price change (1W)
+0.1%
Price change (30D)
-0.7%
Price change (3M)
-15.1%
Price change (6M)
+15.8%
Price change (YTD)
+43.4%
Price change (1Y)
+84.1%
Trailing year
Price change (5Y)
-33.1%
52-week high
$22.95
52-week low
$7.19
Change from 52-week high
-35.3%
Change from 52-week low
+106.4%
Annualized volatility
80.5%
Annualized volatility (3M)
71.6%
Beta
1.6
RSI (14D)
43.5
Price vs SMA 50
-18.8%
Price vs SMA 200
-5.7%
Avg volume (3M)
900,011
Relative volume
0.5
Average dollar volume
$16.32M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
64.35M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
3.0
reciprocal yield 33.7%
FCF yield
—
TTM · current market cap
Buyback yield
0.7%
P / FCF
—
P / operating cash flow
—
Earnings yield
-21.4%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
0.7%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-09-14

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$221.81M
Net income (TTM)
−$204.69M
Trailing 12 months
Diluted EPS (TTM)
$-2.84
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.00
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-3.81
EBITDA per diluted share (TTM)
$-3.80
Net income per diluted share (TTM)
$-2.87
Operating cash flow per diluted share (TTM)
$-2.56
Free cash flow per diluted share (TTM)
$-2.56
Capital expenditures per diluted share (TTM)
$0.00
R&D per diluted share (TTM)
$2.79
Stock compensation per diluted share (TTM)
$0.72
Book value per share
$6.78

Growth

11 metrics
Revenue growth YoY
-100.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
$0
Trailing 12 months
EPS growth YoY
-255.0%
Shares change YoY
+36.5%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-63.6%
Return on assets
-56.3%
Debt / equity
0.0
Current ratio
8.4
EBITDA (TTM)
−$221.49M
Free cash flow (TTM)
—
Quick ratio
8.4
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$334.54M
Latest balance sheet
Cash & equivalents
$78.64M
Total assets
$363.79M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$159.25M
Capital expenditures (TTM)
$0
R&D (TTM)
$171.47M
SG&A (TTM)
—
Stock compensation (TTM)
$32.84M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
184
13F filer change QoQ
+10
Institutional ownership
111.8%
Conviction holders (share of 13F filers)
1.6%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+6.5%
Holder tenure
13.2
Price vs estimated holder cost
+2.7%

Ownership (registered funds)

1 metrics
Index-fund ownership
17.0%

Short interest

3 metrics
Short interest
11.9%
Latest settlement · 8.2 days to cover
Days to cover
8.2d
Short-squeeze score
61 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$780,360
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1789972 CUSIP 230031106 13F (30d) 20 filings 20 filers Visit website Investor relations